Identification
Name7-methyl-guanosine-5'-triphosphate-5'-guanosine
Accession NumberDB03958  (EXPT01655)
TypeSmall Molecule
GroupsExperimental
DescriptionNot Available
Structure
Thumb
Synonyms
mRNA cap analog N7-Methyl GpppG
External IDs Not Available
Product Ingredients Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
CategoriesNot Available
UNIINot Available
CAS numberNot Available
WeightAverage: 803.4404
Monoisotopic: 803.095238742
Chemical FormulaC21H30N10O18P3
InChI KeyFHHZHGZBHYYWTG-INFSMZHSSA-O
InChI
InChI=1S/C21H29N10O18P3/c1-29-5-31(15-9(29)17(37)28-21(23)26-15)19-13(35)11(33)7(47-19)3-45-51(40,41)49-52(42,43)48-50(38,39)44-2-6-10(32)12(34)18(46-6)30-4-24-8-14(30)25-20(22)27-16(8)36/h4-7,10-13,18-19,32-35H,2-3H2,1H3,(H8-,22,23,25,26,27,28,36,37,38,39,40,41,42,43)/p+1/t6-,7-,10-,11-,12-,13-,18-,19-/m1/s1
IUPAC Name
9-[(2R,3R,4S,5R)-5-({[({[({[(2R,3S,4R,5R)-3,4-dihydroxy-5-(6-hydroxy-2-imino-3,9-dihydro-2H-purin-9-yl)oxolan-2-yl]methoxy}(hydroxy)phosphoryl)oxy](hydroxy)phosphoryl}oxy)(hydroxy)phosphoryl]oxy}methyl)-3,4-dihydroxyoxolan-2-yl]-6-hydroxy-2-imino-7-methyl-3,9-dihydro-2H-purin-7-ium
SMILES
[H][[email protected]]1(COP(O)(=O)OP(O)(=O)OP(O)(=O)OC[[email protected]@]2([H])O[[email protected]@]([H])(N3C=[N+](C)C4=C3NC(=N)N=C4O)[[email protected]]([H])(O)[[email protected]]2([H])O)O[[email protected]@]([H])(N2C=NC3=C2NC(=N)N=C3O)[[email protected]]([H])(O)[[email protected]]1([H])O
Pharmacology
IndicationNot Available
Structured Indications Not Available
PharmacodynamicsNot Available
Mechanism of action
TargetKindPharmacological actionActionsOrganismUniProt ID
m7GpppX diphosphataseProteinunknownNot AvailableHumanQ96C86 details
RNA-directed RNA polymerase lambda-3ProteinunknownNot AvailableT3DP0CK31 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions Not Available
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB Entries
FDA labelNot Available
MSDSNot Available
Clinical Trials
Clinical Trials Not Available
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility6.06 mg/mLALOGPS
logP-1.1ALOGPS
logP-12ChemAxon
logS-2.1ALOGPS
pKa (Strongest Acidic)0.88ChemAxon
pKa (Strongest Basic)4.95ChemAxon
Physiological Charge-2ChemAxon
Hydrogen Acceptor Count21ChemAxon
Hydrogen Donor Count13ChemAxon
Polar Surface Area411.77 Å2ChemAxon
Rotatable Bond Count12ChemAxon
Refractivity184.44 m3·mol-1ChemAxon
Polarizability67.34 Å3ChemAxon
Number of Rings6ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.9673
Blood Brain Barrier+0.5487
Caco-2 permeable-0.7055
P-glycoprotein substrateSubstrate0.574
P-glycoprotein inhibitor INon-inhibitor0.9279
P-glycoprotein inhibitor IINon-inhibitor0.9825
Renal organic cation transporterNon-inhibitor0.9288
CYP450 2C9 substrateNon-substrate0.7758
CYP450 2D6 substrateNon-substrate0.8301
CYP450 3A4 substrateSubstrate0.5292
CYP450 1A2 substrateNon-inhibitor0.7718
CYP450 2C9 inhibitorNon-inhibitor0.8841
CYP450 2D6 inhibitorNon-inhibitor0.8684
CYP450 2C19 inhibitorNon-inhibitor0.8738
CYP450 3A4 inhibitorNon-inhibitor0.8975
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.955
Ames testNon AMES toxic0.8204
CarcinogenicityNon-carcinogens0.9027
BiodegradationNot ready biodegradable0.9682
Rat acute toxicity2.7349 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.956
hERG inhibition (predictor II)Non-inhibitor0.5494
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of chemical entities known as (5'->5')-dinucleotides. These are dinucleotides where the two bases are connected via a (5'->5')-phosphodiester linkage.
KingdomChemical entities
Super ClassOrganic compounds
ClassNucleosides, nucleotides, and analogues
Sub Class(5'->5')-dinucleotides
Direct Parent(5'->5')-dinucleotides
Alternative ParentsPurine ribonucleoside triphosphates / Purine nucleotide sugars / Purine ribonucleoside monophosphates / Pentose phosphates / Glycosylamines / Hypoxanthines / Monosaccharide phosphates / 6-oxopurines / Aminopyrimidines and derivatives / Monoalkyl phosphates
Substituents(5'->5')-dinucleotide / Purine ribonucleoside triphosphate / Purine nucleotide sugar / Purine ribonucleoside monophosphate / Pentose phosphate / Pentose-5-phosphate / Glycosyl compound / N-glycosyl compound / 6-oxopurine / Hypoxanthine
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Rna 7-methylguanosine cap binding
Specific Function:
Decapping scavenger enzyme that catalyzes the cleavage of a residual cap structure following the degradation of mRNAs by the 3'->5' exosome-mediated mRNA decay pathway. Hydrolyzes cap analog structures like 7-methylguanosine nucleoside triphosphate (m7GpppG) with up to 10 nucleotide substrates (small capped oligoribonucleotides) and specifically releases 5'-phosphorylated RNA fragments and 7-me...
Gene Name:
DCPS
Uniprot ID:
Q96C86
Uniprot Name:
m7GpppX diphosphatase
Molecular Weight:
38608.45 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
T3D
Pharmacological action
unknown
General Function:
Rna-directed rna polymerase activity
Specific Function:
RNA-directed RNA polymerase that is involved in transcription and genome replication. Following infection, it catalyzes the synthesis of fully conservative plus strands. After core assembly, which consists in recruitment of one capped plus-strand for each genomic segments and polymerase complexes, the polymerase switches mode and catalyzes the synthesis of complementary minus-strands.
Gene Name:
L1
Uniprot ID:
P0CK31
Uniprot Name:
RNA-directed RNA polymerase lambda-3
Molecular Weight:
142268.83 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Drug created on June 13, 2005 07:24 / Updated on September 01, 2017 11:11